Joy and happiness to our veterans! The Drug Enforcement Administration has approved the study on medical marijuana effects on PTSD. Post-Traumatic Stress Disorder is a common illness obtained by veterans after participating in conflict zones.
This study will be the first controlled research in the U.S, which will use the plant in its own form instead of oils or synthesized cannabis.
The research is sponsored by the non-profit organization, Multidisciplinary Association for Psychedelic Studies ( MAPS). The MAPS researchers are approved by the DEA to buy the cannabis plant used in the study, from the National Institute for Drug Abuse.
He has also said that the group will be recruiting participants possibly in June or earlier.
The Colorado state has awarded in 2014 a 2$ million grant to MAPS for the research. In the same time, Colorado has also given 5.6$ million to other organizations, showing its support to medical marijuana studies.
The Health and Human Services Department has first approved the research in March 2014. Trials were going to take place at the University of Arizona occurring within a year. But all studies were delayed, after the Tucson, Arizona school finished the contract with Dr. Sue Sisley, the primer researcher in this study. Now, the program is split, with Sisley running in Arizona half the study, and Ryan Vandrey supervising the other half at the Johns Hopkins University in Baltimore, Maryland. The University of Pennsylvania, Perelman School of Medicine with Marcel Bonn-Miller is also overseeing the project, along with the University of Colorado School of Medicine.
The study will use various marijuana strains with different THC and CBD levels which will help them make a comparison. The study will consist in having 76 veteran participants with PTSD treatment-resistance.
Nowadays, the use of medical marijuana to treat PTSD remains disputable. On one side, some veterans said that the plant allowed them to stop using prescription drugs and eases their pain. While, on the other side, there is few scientific research supporting these affirmations.
Amy Emerson, director of clinical research for the MAPS Public Benefit Corporation said:What is your opinion on developing medical marijuana for several disorders?